Soleno Therapeutics (SLNO) Divestments (2016 - 2017)
Soleno Therapeutics (SLNO) reported Divestments of $717000.0 for Q3 2017, up 35750.0% year-over-year from N/an in Q3 2016, and up 23800.0% on a QoQ basis from $3000.0 in Q2 2017.
Soleno Therapeutics (SLNO) has 2 years of Divestments data on file, last reported at $717000.0 in Q3 2017.
- Quarterly Divestments rose 35750.0% year-over-year to $717000.0 in Q3 2017, while the trailing twelve-month figure through Dec 2017 was $716000.0 (changed N/A YoY) and the FY2018 annual result came in at -$172000.0, down 124.02% from the prior year.
- Divestments improved to $717000.0 in Q3 2017 per SLNO's latest filing, from $3000.0 in the prior quarter.
- Across five years, Divestments topped out at $717000.0 in Q3 2017 and bottomed at -$6885.0 in Q4 2016.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 717,000.00 |
| Jun 30, 2017 | 3,000.00 |
| Mar 31, 2017 | -4,000.00 |
| Dec 31, 2016 | -6,885.00 |
| Sep 30, 2016 | 2,000.00 |